New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
11:12 EDTTEVATeva price target raised to $57 from $53 at BMO Capital
BMO Capital raised its price target for Teva shares to $57 after the Supreme Court agreed to hear the company's appeal in its case against Momenta (MNTA), Novartis (NVS) and Mylan (MYL). BMO thinks Copaxone generics will not meaningfully affect 2014 and keeps an Outperform rating on the stock.
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 16, 2014
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use